BIOLASE (NASDAQ:BIOL) Now Covered by StockNews.com

Research analysts at StockNews.com began coverage on shares of BIOLASE (NASDAQ:BIOLGet Rating) in a research note issued on Monday. The firm set a “sell” rating on the medical technology company’s stock.

A number of other research analysts also recently weighed in on the company. Colliers Securities reissued a “buy” rating on shares of BIOLASE in a report on Tuesday, March 22nd. Lake Street Capital started coverage on BIOLASE in a report on Friday, May 20th. They issued a “buy” rating and a $12.00 target price on the stock. Finally, Maxim Group started coverage on BIOLASE in a report on Friday, March 18th. They issued a “buy” rating and a $37.50 target price on the stock. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $41.50.

BIOLASE stock opened at $4.57 on Monday. The company has a debt-to-equity ratio of 0.66, a current ratio of 3.34 and a quick ratio of 2.22. BIOLASE has a one year low of $3.30 and a one year high of $23.49. The stock has a market capitalization of $28.22 million, a PE ratio of -2.22 and a beta of 1.55. The business’s fifty day moving average is $6.78 and its 200 day moving average is $8.27.

BIOLASE (NASDAQ:BIOLGet Rating) last released its quarterly earnings data on Thursday, May 12th. The medical technology company reported ($0.81) EPS for the quarter. BIOLASE had a negative net margin of 34.03% and a negative return on equity of 62.40%. The business had revenue of $10.17 million for the quarter.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. State Street Corp raised its stake in shares of BIOLASE by 4.5% in the first quarter. State Street Corp now owns 436,076 shares of the medical technology company’s stock worth $154,000 after buying an additional 18,682 shares during the period. Essex Investment Management Co. LLC raised its stake in shares of BIOLASE by 2.5% in the first quarter. Essex Investment Management Co. LLC now owns 1,621,992 shares of the medical technology company’s stock worth $573,000 after buying an additional 39,281 shares during the period. Commonwealth Equity Services LLC raised its stake in shares of BIOLASE by 117.8% in the first quarter. Commonwealth Equity Services LLC now owns 101,046 shares of the medical technology company’s stock worth $35,000 after buying an additional 54,650 shares during the period. Finally, Acadian Asset Management LLC bought a new position in shares of BIOLASE in the fourth quarter worth about $31,000. 11.38% of the stock is currently owned by hedge funds and other institutional investors.

About BIOLASE (Get Rating)

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications.

See Also

Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.